Dallas Salazar

Amit Dayal

Ning Jia

- Vivani Medical Inc. (VANI) is developing **subdermal biopharmaceutical implants** using its proprietary NanoPortal platform to address medication non-adherence in chronic diseases, with an initial focus on the GLP-1 space for obesity and diabetes.  **[1266806_2157827_1]** **[1266806_2157827_3]** 
- The company's lead program, a **semaglutide implant (NPM 139)**, demonstrated **approximately 20% weight loss over a seven-month period** in preclinical studies.  **[1266806_2157827_3]** **[1266806_2157827_6]** 
- Following a successful first-in-human study for its exenatide implant technology, Vivani Medical anticipates initiating clinical development for the semaglutide implant in the **first half of next year**.  **[1266806_2157827_3]** **[1266806_2157827_6]** 
- Vivani Medical announced a spin-off of its subsidiary, Cortigent, with shareholders holding common stock as of **October 8** eligible to receive a dividend of Cortigent shares.  **[1266806_2157827_7]**

Vivani Medical Details Progress on GLP-1 Implant Programs and Cortigent Spin-off

- Vivani Medical, Inc. (VANI) has set **October 8, 2025**, as the **record date** for the spin-off of its wholly-owned subsidiary, Cortigent, Inc..  **[1266806_0001753926-25-001510_vani-20250917.htm:1]** **[1266806_0001753926-25-001510_ex991_1.htm:1]** 
- Vivani stockholders holding common stock as of the record date will receive common stock in Cortigent.  **[1266806_0001753926-25-001510_vani-20250917.htm:1]** **[1266806_0001753926-25-001510_ex991_1.htm:1]**  Cortigent, which develops brain implant devices with neuromodulation technology, is expected to trade on the Nasdaq Stock Market under the ticker symbol **"CRGT"**.  **[1266806_0001753926-25-001510_ex991_1.htm:1]** 
- Following the spin-off, Vivani Medical will sharpen its focus on developing miniature, ultra long-acting GLP-1 implants for weight loss management and type 2 diabetes.  **[1266806_0001753926-25-001510_ex991_1.htm:1]** **[1266806_0001753926-25-001510_ex991_1.htm:2]**  The spin-off is estimated to be complete by **late-2025**.  **[1266806_0001753926-25-001510_ex991_1.htm:2]**

Vivani Medical (VANI)